Search Results - "Vergniol J"

Discordance Between FIB-4 and BAST Fibrosis Risk Classifications in Obese Patients with MASLD: Results from the OBREDI-TR Study.

Authors: Kama Basci, Ozge Oral, Alihan Kirik, Ali et al.

Source: Diagnostics (2075-4418). Feb2026, Vol. 16 Issue 4, p547. 12p.

Commentary: prognostication of chronic hepatitis B - are Fibrotest and Fibroscan the final answers? Authors' reply.

Authors: de Lédinghen V Vergniol J

Source: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2013 Jun; Vol. 37 (11), pp. 1114.

Publication Type: Journal Article; Comment

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE

Sexual Functioning of Patients with Inflammatory Bowel Disease.

Authors: Kotkowicz-Szczur, Marta Kisielewska, Lidia Kisielewski, Rafal et al.

Source: Journal of Clinical Medicine. Mar2026, Vol. 15 Issue 6, p2379. 10p.

LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries.

Authors: Graupera, Isabel Thiele, Maja Ma, Ann T. et al.

Source: BMC Public Health. 7/19/2022, Vol. 22 Issue 1, p1-10. 10p. 1 Color Photograph, 1 Diagram, 1 Chart.

The Relationship Between Fibrosis-4 Score and Major Cardiovascular Events and Mortality in Patients Under 40 Years of Age with Acute Myocarditis.

Authors: Altuntaş, Emine Sadıkoğlu, Kadir Balçın, Kübra et al.

Source: Istanbul Medical Journal. May2026, Vol. 27 Issue 2, p149-154. 6p.

Discordance Between Conventional Ultrasound and Transient Elastography in Hepatic Steatosis Assessment: Clinical Factors Associated with Discrepant Findings.

Authors: Brisc, Mihaela Cristina Babeș, Elena Emilia Călugăr-Șolea, Sabina Florina et al.

Source: Diagnostics (2075-4418). Apr2026, Vol. 16 Issue 8, p1188. 14p.

Saroglitazar for non-obese metabolic-dysfunction associated steatotic liver disease (MASLD): An open-label randomised controlled trial.

Authors: Bhagat, Naveen De, Arka Duseja, Ajay et al.

Source: Indian Journal of Medical Research. Apr2026, Vol. 163 Issue 4, p1-9. 9p.

Physiological Mechanism of Pulsatility of Portal Venous Flow in Healthy Adults.

Authors: Onoda, Airi Murayama, Michito Wadayama, Moe et al.

Source: Applied Sciences (2076-3417); Sep2025, Vol. 15 Issue 17, p9334, 15p

Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co‐infected HIV patients with cirrhosis.

Authors: Willemse, Sophie Smit, Colette Sogni, Philippe et al.

Source: Journal of Viral Hepatitis. Oct2019, Vol. 26 Issue 10, p1224-1228. 5p.

Cirrhotic Cardiomyopathy: Prevalence and Clinical Impact on Liver Cirrhosis Outcomes.

Authors: Kitagataya, Takashi Suda, Goki Tanaka, Takatsugu et al.

Source: Hepatology Research. Oct2025, Vol. 55 Issue 10, p1367-1375. 9p.

Distribution of Fibrosis‐4 index and vibration‐controlled transient elastography‐derived liver stiffness measurement for patients with metabolic dysfunction‐associated steatotic liver disease in health check‐up.

Authors: Ogawa, Yuji Tomeno, Wataru Imamura, Yasushi et al.

Source: Hepatology Research. Feb2025, Vol. 55 Issue 2, p191-199. 9p.

Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study).

Authors: Huang, Chung-Feng Heo, Jeong Chien, Rong-Nan et al.

Source: Infectious Diseases & Therapy. May2025, Vol. 14 Issue 5, p1089-1101. 13p.

Ultrasound Attenuation Coefficient as a Biomarker of Hepatic Steatosis: State of the Art and Software Evaluation.

Authors: Esposto, Giorgio Iaccarino, Jacopo Camilli, Sara et al.

Source: Journal of Clinical Medicine. Mar2026, Vol. 15 Issue 5, p1816. 16p.

The Role of Primary Care and Noninvasive Testing in the Early Diagnosis of Metabolic-Associated Steatotic Liver Disease (MASLD).

Authors: Constantin, Alina Mihaela Nedelescu, Mirela Maria Tatar, Raluca et al.

Source: Gastroenterology Insights. Mar2026, Vol. 17 Issue 1, p11. 17p.

Prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease in Craniopharyngioma Patients Using Non-Invasive Investigations.

Authors: Nitya, Anurag A. V. Ghosh, Jayaditya Taneja, Sunil et al.

Source: Indian Journal of Endocrinology & Metabolism. Jan/Feb2026, Vol. 30 Issue 1, p79-84. 6p.

Direct comparison of ultrasound-guided attenuation parameter and controlled attenuation parameter for steatosis using MRI-based proton density fat fraction as a reference.

Authors: Imajo, Kento Toyoda, Hidenori Yasuda, Satoshi et al.

Source: Ultrasonography. Jan2026, Vol. 45 Issue 1, p9-17. 9p.

Validation study of age‐independent fibrosis score (Fibrosis‐3 index) in patients with metabolic dysfunction‐associated steatotic liver disease.

Authors: Nouso, Kazuhiro Kawanaka, Miwa Fujii, Hideki et al.

Source: Hepatology Research. Oct2024, Vol. 54 Issue 10, p912-920. 9p.

Contrast‐Enhanced Computed Tomography/Magnetic Resonance Imaging Is Useful for Surveying Gastroesophageal Varices in Patients After Fontan Surgery.

Authors: Suzuki, Takanori Matsuura, Kentaro Yamabe, Sayuri et al.

Source: Hepatology Research. Sep2025, Vol. 55 Issue 9, p1320-1326. 7p.

Predicting the risk of developing diabetes in steatotic liver disease using controlled attenuation parameter in a health checkup population.

Authors: Nakatsuka, Takuma Yamaji, Yutaka Tateishi, Ryosuke et al.

Source: Hepatology Research. Aug2025, Vol. 55 Issue 8, p1101-1110. 10p.

Comparison Between Transient Elastography and Point Shear Wave Elastography in the Assessment of Liver Fibrosis According to the Grade of Liver Steatosis.

Authors: Losurdo, Giuseppe Castellaneta, Antonino Di Nuccio, Claudia et al.

Source: Journal of Clinical Medicine. 8/1/2025, Vol. 14 Issue 15, p5417. 12p.